Abstract
More than twenty years ago Rinderknecht et al. identified a minor trypsin isoform resistant to natural trypsin inhibitors in the human pancreatic juice. At the same time, Estell and Laskowski found that an inhibitor-resistant trypsin from the pyloric caeca of the starfish, Dermasterias imbricata rapidly hydrolyzed the reactive-site peptide bonds of trypsin inhibitors. A connection between these two seminal discoveries was made recently, when human mesotrypsin was shown to cleave the reactive-site peptide bond of the Kunitz-type soybean trypsin inhibitor, and degrade the Kazal-type pancreatic secretory trypsin inhibitor. These observations indicate that proteases specialized for the degradation of protease inhibitors are ubiquitous in metazoa, and prompt new investigations into their biological significance. Here we review the history and properties of human mesotrypsin, and discuss its function in the digestive degradation of dietary trypsin inhibitors and possible pathophysiological role in pancreatitis.
Keywords: trypsinogen, proteomics, t cell receptor genes, mesotrypsin, polypeptide inhibitors, enteropeptidase, duodenum
Protein & Peptide Letters
Title: Human Mesotrypsin Defies Natural Trypsin Inhibitors: From Passive Resistance to Active Destruction.
Volume: 12 Issue: 5
Author(s): Miklos Sahin-Toth
Affiliation:
Keywords: trypsinogen, proteomics, t cell receptor genes, mesotrypsin, polypeptide inhibitors, enteropeptidase, duodenum
Abstract: More than twenty years ago Rinderknecht et al. identified a minor trypsin isoform resistant to natural trypsin inhibitors in the human pancreatic juice. At the same time, Estell and Laskowski found that an inhibitor-resistant trypsin from the pyloric caeca of the starfish, Dermasterias imbricata rapidly hydrolyzed the reactive-site peptide bonds of trypsin inhibitors. A connection between these two seminal discoveries was made recently, when human mesotrypsin was shown to cleave the reactive-site peptide bond of the Kunitz-type soybean trypsin inhibitor, and degrade the Kazal-type pancreatic secretory trypsin inhibitor. These observations indicate that proteases specialized for the degradation of protease inhibitors are ubiquitous in metazoa, and prompt new investigations into their biological significance. Here we review the history and properties of human mesotrypsin, and discuss its function in the digestive degradation of dietary trypsin inhibitors and possible pathophysiological role in pancreatitis.
Export Options
About this article
Cite this article as:
Sahin-Toth Miklos, Human Mesotrypsin Defies Natural Trypsin Inhibitors: From Passive Resistance to Active Destruction., Protein & Peptide Letters 2005; 12 (5) . https://dx.doi.org/10.2174/0929866054395356
DOI https://dx.doi.org/10.2174/0929866054395356 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Tumor Dormancy and the Angiogenic Switch: Possible Implications of Bone Marrow- Derived Cells
Current Pharmaceutical Design Alternative Splicing and Tumor Progression
Current Genomics Pharmacogenomics of Cytochrome P450 Enzymes in Tumours
Current Pharmacogenomics Recent Progress in the Development of Natural ent-Kaurane Diterpenoids with Anti-tumor Activity
Mini-Reviews in Medicinal Chemistry PI3K Inhibitors for Cancer Therapy: What has been Achieved So Far?
Current Medicinal Chemistry The Clustered DNA Lesions – Types, Pathways of Repair and Relevance to Human Health
Current Medicinal Chemistry Advancing Drug Therapy for Brain Tumours: A Current Review of the Pro-inflammatory Peptide Substance P and its Antagonists as Anti-cancer Agents
Recent Patents on CNS Drug Discovery (Discontinued) Targeting Heat Shock Protein 90 for Malaria
Mini-Reviews in Medicinal Chemistry Sunlight Vitamin D and Skin Cancer
Anti-Cancer Agents in Medicinal Chemistry Reversion of Multidrug Resistance in Tumor By Biocompatible Nanomaterials
Mini-Reviews in Medicinal Chemistry MicroRNAs in Human Diseases
Recent Patents on DNA & Gene Sequences Role of C1QBP/p32 and its Therapeutic Potential in Breast Carcinoma and other Cancers
Current Medicinal Chemistry Advances in Photodynamic Therapy of Cancer
Current Cancer Therapy Reviews Role of the RAS in Pancreatic Cancer
Current Cancer Drug Targets Relevance of the Deletion Polymorphisms of the Glutathione S-Transferases GSTT1 and GSTM1 in Pharmacology and Toxicology
Current Drug Metabolism Recent Advances in Curcumin Treated Non-Small Cell Lung Cancers: An Impetus of Pleiotropic Traits and Nanocarrier Aided Delivery
Current Medicinal Chemistry Automated PET Radiotracer Manufacture on the BG75 System and Imaging Validation Studies of [18F]fluoromisonidazole ([18F]FMISO)
Current Radiopharmaceuticals Characterization of Pharmaceutical IgG and Biosimilars Using Miniaturized Platforms and LC-MS/MS
Current Pharmaceutical Biotechnology Differences in Phosphorylated Histone H2AX Foci Formation and Removal of Cells Exposed to Low and High Linear Energy Transfer Radiation
Current Genomics Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck
Anti-Cancer Agents in Medicinal Chemistry